Evidence map›Paper›PMID 42733745›Full record

ArticleiScience2026

SCLC TumorMiner: A genomics platform for small cell lung cancer precision oncology.

Fathi Elloumi, Anjali Dhall, Daiki Taniyama, Augustin Luna, Yasuhiro Arakawa, Sudhir Varma, Yanghsin Wang, Anisha Tehim, Mark Raffeld, Kenneth Aldape and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Fathi ElloumiLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Anjali DhallLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Daiki TaniyamaLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Augustin LunaLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Yasuhiro ArakawaLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Sudhir VarmaLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Yanghsin WangLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Anisha TehimLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Mark RaffeldLaboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Kenneth AldapeLaboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Christophe RedonLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Roshan ShresthaLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
William ReinholdLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Mirit AladjemLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Jaydira Del RiveroLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Nitin RoperLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Anish ThomasLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Yves PommierLaboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.

Funding

Computational Analysis of Drug Response in Biological NetworksZIALM240126 · NLM · NATIONAL LIBRARY OF MEDICINE · PI LUNA, AUGUSTIN · 2024 to 2025
$1.8M
PROTEIN-ASSOCIATED DNA BREAKS AS INDICATOR OF TOPOISOMERASE INHIBITIONZ01BC006150 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI POMMIER, YVES · 1996 to 2008
$1.5M
Intramural NIH HHS Z01 BC006150Intramural NIH HHS ZIA LM240126
6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is among the most aggressive malignancies. Unlike many other cancers, it is not represented in The Cancer Genome Atlas, and available datasets are fragmented across institutions, disease stages, and treatment settings. RNA sequencing provides a powerful and cost-effective approach, but the high dimensionality of transcriptomic data and the heterogeneity of patient cohorts pose significant challenges. To address such challenges, we developed SCLC TumorMiner (https://discover.nci.nih.gov/SclcTumorMinerCDB/), which includes 50 tumor samples from relapsed patients at the National Cancer Institute (NCI) and 154 samples from untreated patients at the University of Cologne and Tongji University. SCLC TumorMiner enables molecular classification, genomic pathway analyses, risk stratification, identification of predictive cell-surface biomarkers such as

Indexed as

cell surface targets for immune therapiespatient clinical and genomics dataSCLCSCLC primary and relapse classificationSCLC TumorMiner web portalsmall cell lung cancer

Identifiers

PMID42733745
PMCPMC13571741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.